Do You Still Need Noom Med's App for GLP-1 Maintenance? (2026) | Luma Health
Clinical Guidance · 2026

Do You Still Need
Noom Med's App for Maintenance?

Quick Verdict

Noom Med's app-based coaching model is built for active behavior change during initial weight loss; once you're in maintenance, the ongoing app subscription cost often outlasts its usefulness for many patients.

Luma Health's flat semaglutide ($197/month) and tirzepatide ($297/month) stay the same price through maintenance, with no app subscription to reassess.

Noom Med's coaching app is genuinely useful for many patients during active weight loss, when daily habit-building content and food logging support real behavior change. The question worth revisiting once you reach maintenance is whether that same bundled cost still matches what you need.

Why Maintenance Needs Are Different

During active weight loss, structured daily engagement can genuinely help build new habits. Once you've reached a stable weight, many patients find they've internalized those habits and no longer need daily app-based coaching to maintain them — what matters more at that stage is consistent medication access and periodic provider check-ins, not ongoing behavioral curriculum.

Reassessing the Bundle at Maintenance

If you're in maintenance and still paying Noom Med's combined app-and-medication price, it's worth asking whether you're still actively using the coaching features, or whether you've settled into habits that no longer require daily prompting. If it's the latter, a focused, medication-only provider can maintain your treatment at a lower ongoing cost without the bundled app.

What Maintenance Actually Requires

Long-term GLP-1 maintenance mainly requires: consistent medication access without supply gaps, periodic provider check-ins to confirm your dose is still appropriate, and a straightforward refill process. None of these inherently require an active behavioral-coaching app subscription once your habits are established.

The Cost Difference Over Years of Maintenance

Since most GLP-1 patients continue treatment long-term rather than stopping, the cost of a bundled app subscription compounds meaningfully over years. If Noom Med's combined price runs $100-$200/month more than a focused alternative, that's $1,200-$2,400+ per year, every year, for coaching content you may no longer be actively using.

Reassessing Your Own Situation

Keep the bundled app if you…
  • Still actively use its coaching features regularly
  • Find ongoing value in the daily engagement structure
  • Aren't primarily focused on minimizing long-term cost
Consider switching for maintenance if you…
  • Have stopped actively engaging with the coaching app
  • Have internalized the habits that matter for your maintenance
  • Want to reduce recurring cost for a treatment you'll continue long-term

Built for the
long haul

Compounded semaglutide at $197/month or tirzepatide at $297/month — the same flat price through your active phase and your maintenance phase.

Get Started → Or start your free health assessment

Frequently Asked Questions

Not necessarily. Many patients find they've internalized the habits built during active weight loss and no longer need daily app-based coaching to maintain them.

Mainly consistent medication access, periodic provider check-ins, and a straightforward refill process — not necessarily an ongoing behavioral-coaching app subscription.

Potentially $1,200-$2,400+ per year if Noom Med's bundled price runs $100-$200/month more than a focused, medication-only alternative.

Not if you share your current dose and treatment history with your new provider, allowing them to continue your maintenance dose without unnecessary changes.

In some cases, yes — Noom's coaching app has been available as a standalone subscription apart from the medication program. Confirm current availability directly with Noom.

No. The $197/month semaglutide and $297/month tirzepatide price is flat throughout both active treatment and maintenance.

References

  1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
Medical Disclaimer: This article is for educational purposes and is not a substitute for professional medical advice. Individual results and needs vary; consult a licensed healthcare provider before starting, stopping, or changing any treatment or supplement. This article reflects information available as of July 2026. Luma Health's compounded medications are not themselves FDA-approved as finished drug products; their active ingredients are FDA-approved in commercial formulations such as Ozempic, Wegovy, Mounjaro, and Zepbound.